awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q49886531-53E8417D-F8C4-42DC-9BC4-6A2EEE20A1B7
Q49886531-53E8417D-F8C4-42DC-9BC4-6A2EEE20A1B7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49886531-53E8417D-F8C4-42DC-9BC4-6A2EEE20A1B7
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
P2860
Q49886531-53E8417D-F8C4-42DC-9BC4-6A2EEE20A1B7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49886531-53E8417D-F8C4-42DC-9BC4-6A2EEE20A1B7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4b850770c6e3f33f6d82b63565c77f25b246270a
P2860
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.